This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Services Related articles in Am J Pathol Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sanders, M. E. Articles by Barr, F. G. Search for Related Content PubMed PubMed Citation Articles by Sanders, M. E. Articles by Barr, F. G.

(American Journal of Pathology. 2002;161:997-1005.)
© 2002 American Society for Investigative Pathology

Regular Articles

Unique Patterns of Allelic Imbalance Distinguish Type 1 from Type 2 Sporadic Papillary Renal Cell Carcinoma

Melinda E. Sanders^*, Rosemarie Mick, John E. Tomaszewski^* and Frederic G. Barr^*

From the Departments of Pathology and Laboratory Medicine^* and Biostatistics and Epidemiology, the University of Pennsylvania Medical Center, and the University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania

The molecular genetic correlates of a recently proposed subclassification of papillary renal cell carcinoma (PRCC) that designates tumors as type 1 and type 2 based on histological features have not yet been established. Alterations of known genes in PRCC include missense mutations in the MET oncogene (7q31) and rare translocations fusing TFE3 at Xp11.2 with a variety of other loci. Previous cytogenetic and allelic loss studies of PRCC cases revealed gain of chromosome 3q, 7, 8, 12q, 16, 17, and 20q, and loss of 1p, 6q, 9p, 11p, 13q, 14q, 18, 21q, X, and Y. We analyzed a series of sporadic type 1 and type 2 PRCC cases for MET mutations, TFE3 rearrangements, and allelic imbalance (AI) on 3p, 6, 7q, 9p, 11, 13q, 14q, 17q, 18, 20q, and 21q and compared selected results with a series of conventional renal cell carcinomas. A somatic mutation M1149T was identified in MET exon 17 in 1 of 35 PRCC cases whereas TFE3 rearrangements were not detected in 22 PRCC cases examined. Significant differences in AI frequency between PRCCs and conventional renal cell carcinoma cases were seen on 3p (37.5% versus 77.8%, P = 0.01), 7q (42.9% versus 5.6%, P = 0.01), and 17q (54.5% versus 20.0%, P = 0.03). Significant differences in AI frequency between type 1 and type 2 PRCCs were noted on 17q (78.6% versus 12.5%, P = 0.006) and 9p (0% versus 37.5%, P = 0.02). Additional analyses suggested that the relationship between 17q AI and PRCC type may be independent of histological grade and stage. Our findings identify genetic differences between the recently proposed type 1 and type 2 PRCCs, and support the premise that these subtypes arise from distinct genetic pathways.

Related articles in Am J Pathol:

This Month in AJP

Am J Pathol 2002 161: 743-744. [Full Text]  

This article has been cited by other articles:

				I Balint, A Szponar, A Jauch, and G Kovacs Trisomy 7 and 17 mark papillary renal cell tumours irrespectively of variation of the phenotype J. Clin. Pathol., October 1, 2009; 62(10): 892 - 895. [Abstract] [Full Text] [PDF]

				T. Klatte, A. J. Pantuck, J. W. Said, D. B. Seligson, N. P. Rao, J. C. LaRochelle, B. Shuch, A. Zisman, F. F. Kabbinavar, and A. S. Belldegrun Cytogenetic and Molecular Tumor Profiling for Type 1 and Type 2 Papillary Renal Cell Carcinoma Clin. Cancer Res., February 15, 2009; 15(4): 1162 - 1169. [Abstract] [Full Text] [PDF]

				O. Iliopoulos Molecular Biology of Renal Cell Cancer and the Identification of Therapeutic Targets J. Clin. Oncol., December 10, 2006; 24(35): 5593 - 5600. [Abstract] [Full Text] [PDF]

				W. M. Stadler Therapeutic Options for Variant Renal Cancer: A True Orphan Disease Clin. Cancer Res., September 15, 2004; 10(18): 6393S - 6396S. [Abstract] [Full Text] [PDF]

				B. Gunawan, A. von Heydebreck, T. Fritsch, W. Huber, R.-H. Ringert, G. Jakse, and L. Fuzesi Cytogenetic and Morphologic Typing of 58 Papillary Renal Cell Carcinomas: Evidence for a Cytogenetic Evolution of Type 2 from Type 1 Tumors Cancer Res., October 1, 2003; 63(19): 6200 - 6205. [Abstract] [Full Text] [PDF]